Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Hikma Pharmaceuticals PLC

For 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 760* high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 8 R&D centres and c9,100 employees worldwide. 

*As of February 2024

Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668

For all product information and enquiries, please contact us at PV@hikma.com 

Hikma Pharmaceuticals

Discover our exceptional track record at Hikma CMO. When you partner with us to produce your medicines, you’re accessing the same state-of-the-art 1,000,000 Sq. Ft. facility on 80 acres that the FDA has repeatedly used as a training site for qualifying new inspectors within their organization. With zero critical FDA observations for two decades, and best-in-class TRIR safety performance, you can lean on us for all your CMO needs. 
Meet Hikma’s CMO team at Interphex NYC April 16-18th at Booth #1154
#HikmaUS #HikmaCMO #Interphex2024


Aligned with our commitment to inspiring future pioneers, #Hikma #Portugal welcomed students from Alto dos Moinhos school, to our manufacturing plant in Sintra. The immersive tour bridged classroom learning, with real-world pharmaceutical operations, empowering the next generation through experiences that bring science to life. 

#FutureLeaders #YouthEmpowerment #PharmaCareers #STEMEducation 

#Hikma beim Prospitalia Kongress 2024 in Frankfurt 
Der Prospitalia Kongress findet vom 15. bis 16. April 2024 im Kap Europa in Frankfurt statt.  

Leopold Lindauer und Kristina Stumpf freuen sich auf Ihren Besuch und spannende Gespräche an unserem Stand Nr. E1.14. 

Hikma beliefert Apotheken und Krankenhäuser mit generischen injizierbaren Produkten, die in unseren sechs Produktionsstätten für injizierbare Arzneimittel in den USA, Europa und MENA hergestellt werden.  

#BetterHealth #WithinReach #EveryDay

On #WorldHealthDay, #Hikma is proud to champion equitable access to high-quality, affordable medicines for all. We take pride in the important role we play in manufacturing and providing affordable, high-quality medicines to treat a growing number of illnesses and conditions. Our customers, healthcare professionals and patients, look to us to meet their evolving needs and ensure reliable access to essential medicines. 

https://lnkd.in/eG5VmEEZ  

#WorldHealthDay #WHO #BetterHealthForAll #AccessToMedicine #MyHealthMyRight 

Hikma CMO delivers at the speed you demand, and we’re laser-focused on delivering agility, reliability and scalability. In under 24 months, our highly trained #Columbus, Ohio team recently brought to market a critical life-saving device using our effective, robust, and rapid-tech transfer process. Our proven drug technology capabilities can manufacture a broad range of dosage forms, with high-containment operations (HCO), nasal, liquids, bottle, blister, and bulk packaging options. 
Meet our team at Interphex NYC April 16-18th at Booth #1154
#HikmaUS #HikmaCMO #Interphex2024


Today, we proudly celebrate Tareq Darwazeh, our Chief Operating Officer for the #MENA region at #Hikma, recognised as a 2024 Young Global Leader by the World Economic Forum.

This underscores Tareq's #visionaryleadership, driving #innovation and advancement in the MENA pharmaceutical industry, and highlights his commitment to forging positive change in our communities for a more #inclusive and #sustainable world. 

Tareq joins outstanding young pioneers, representing the best of their generation globally. 

#WEF #YGL #YGL24 

	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	1.49B -	1.44B 3.29%	1.95B 35.42%	1.94B 0.72%	2.07B 6.92%	2.21B 6.62%	2.34B 6.07%	2.55B 9.06%	2.52B 1.41%	2.88B 14.22%
cost of revenue	670M -	622M 7.16%	1B 60.77%	1.02B 2.10%	1.07B 4.41%	1.11B 3.94%	1.13B 1.81%	1.25B 10.99%	1.28B 2.16%	1.49B 16.11%
gross profit	819M -	818M 0.12%	950M 16.14%	915M 3.68%	1.00B 9.73%	1.10B 9.46%	1.21B 10.37%	1.30B 7.25%	1.24B 4.84%	1.39B 12.28%
selling and marketing expenses	171M -	172M 0.58%	221M 28.49%	236M 6.79%	224M 5.08%	494M 120.54%	42M 91.50%
general and administrative expenses	174M -	180M 3.45%	208M 15.56%	238M 14.42%	246M 3.36%	-7M 102.85%	464M 6,728.57%	488M 5.17%	509M 4.30%	544M 6.88%
selling general and administrative expenses	345M -	352M 2.03%	429M 21.88%	474M 10.49%	467M 1.48%	487M 4.28%	506M 3.90%	488M 3.56%	509M 4.30%	544M 6.88%
research and development expenses	55M -	36M 34.55%	150M 316.67%	121M 19.33%	147M 21.49%	150M 2.04%	137M 8.67%	143M 4.38%	144M 0.70%	149M 3.47%
other expenses								111M -	103M 7.21%
cost and expenses	1.11B -	1.08B 2.43%	1.69B 56.27%	2.63B 54.96%	1.74B 33.75%	1.69B 3.05%	1.75B 3.74%	1.99B 14.01%	2.04B 2.06%	2.27B 11.55%
operating expenses	441M -	462M 4.76%	694M 50.22%	1.60B 131.12%	673M 58.04%	578M 14.12%	621M 7.44%	742M 19.48%	756M 1.89%	785M 3.84%
interest expense	38M -	57M 50%	104M 82.46%	60M 42.31%	80M 33.33%	67M 16.25%	56M 16.42%	69M 23.21%	77M 11.59%	90M 16.88%
ebitda	481M -	459M 4.57%	506M 10.24%	461M 8.89%	527M 14.32%	584M 10.82%	654M 11.99%	735M 12.39%	700M 4.76%	871M 24.43%
operating income	419M -	393M 6.21%	401M 2.04%	336M 16.21%	428M 27.38%	486M 13.55%	540M 11.11%	582M 7.78%	507M 12.89%	367M 27.61%
depreciation and amortization	62M -	66M 6.45%	105M 59.09%	125M 19.05%	99M 20.80%	98M 1.01%	114M 16.33%	153M 34.21%	193M 26.14%	259M 34.20%
total other income expenses net	-57M -	-75M 31.58%	-191M 154.67%	-1.07B 462.30%	-135M 87.43%	5M 103.70%	18M 260%	-38M 311.11%	-274M 621.05%	-86M 68.61%
income before tax	362M -	318M 12.15%	210M 33.96%	-738M 451.43%	293M 139.70%	491M 67.58%	558M 13.65%	544M 2.51%	233M 57.17%	281M 20.60%
income tax expense	80M -	64M 20%	52M 18.75%	101M 94.23%	8M 92.08%	4M 50%	128M 3,100%	124M 3.13%	42M 66.13%	89M 111.90%
net income	278M -	252M 9.35%	155M 38.49%	-843M 643.87%	282M 133.45%	486M 72.34%	431M 11.32%	421M 2.32%	188M 55.34%	190M 1.06%
weighted average shs out	198M -	199M 0.51%	233M 17.09%	240M 3.00%	241M 0.42%	242M 0.41%	236M 2.48%	231M 2.12%	224M 3.03%	220.86M 1.40%
weighted average shs out dil	200M -	201M 0.50%	234M 16.42%	240M 2.56%	242M 0.83%	243M 0.41%	238M 2.06%	233M 2.10%	225M 3.43%	222.37M 1.17%
eps	1.40 -	1.27 9.29%	0.67 47.24%	-3.51 623.88%	1.17 133.33%	2.01 71.79%	1.83 8.96%	1.82 0.55%	0.84 53.85%	0.86 2.38%
epsdiluted	1.39 -	1.25 10.07%	0.66 47.20%	-3.51 631.82%	1.17 133.33%	2 70.94%	1.81 9.50%	1.81 0%	0.84 53.59%	0.85 1.19%

COM:HIKMA

Hikma Pharmaceuticals

Last Close

2,164.00

07/03 18:28

Market Cap

40.38M

Beta: -

Volume Today

512.60K

Avg: -

Preview